Limits...
(18)F-fluorodeoxyglucose positron emission tomography/computed tomography accuracy in the staging of non-small cell lung cancer: review and cost-effectiveness.

Gómez León N, Escalona S, Bandrés B, Belda C, Callejo D, Blasco JA - Radiol Res Pract (2014)

Bottom Line: Results.Incremental cost-effectiveness of PET/CT over CT alone was €17,412 quality-adjusted life-year (QALY).Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Research Institute La Princesa, La Princesa University Hospital, C/Diego de León 62, 28006 Madrid, Spain.

ABSTRACT
Aim of the performed clinical study was to compare the accuracy and cost-effectiveness of PET/CT in the staging of non-small cell lung cancer (NSCLC). Material and Methods. Cross-sectional and prospective study including 103 patients with histologically confirmed NSCLC. All patients were examined using PET/CT with intravenous contrast medium. Those with disease stage ≤IIB underwent surgery (n = 40). Disease stage was confirmed based on histology results, which were compared with those of PET/CT and positron emission tomography (PET) and computed tomography (CT) separately. 63 patients classified with ≥IIIA disease stage by PET/CT did not undergo surgery. The cost-effectiveness of PET/CT for disease classification was examined using a decision tree analysis. Results. Compared with histology, the accuracy of PET/CT for disease staging has a positive predictive value of 80%, a negative predictive value of 95%, a sensitivity of 94%, and a specificity of 82%. For PET alone, these values are 53%, 66%, 60%, and 50%, whereas for CT alone they are 68%, 86%, 76%, and 72%, respectively. Incremental cost-effectiveness of PET/CT over CT alone was €17,412 quality-adjusted life-year (QALY). Conclusion. In our clinical study, PET/CT using intravenous contrast medium was an accurate and cost-effective method for staging of patients with NSCLC.

No MeSH data available.


Related in: MedlinePlus

Images for a 60-year-old man. (a) CT image of an NSCLC primary tumor (epidermoid carcinoma) in the right upper lobe. (b) PET image showing intense 18F-FDG uptake. (c) PET/CT image showing tumor localisation and radiotracer uptake. (d) Coronal whole-body PET image.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4238277&req=5

fig2: Images for a 60-year-old man. (a) CT image of an NSCLC primary tumor (epidermoid carcinoma) in the right upper lobe. (b) PET image showing intense 18F-FDG uptake. (c) PET/CT image showing tumor localisation and radiotracer uptake. (d) Coronal whole-body PET image.

Mentions: Forty of the 103 patients (38.8%, 36 men and four women) were classified by PET/CT and histology as candidates for surgery; nine of these patients had stage IA disease, 11 had stage IB disease, six had stage IIB disease,12 had stage IIIA disease, and two had stage IIIB disease (Figure 2).


(18)F-fluorodeoxyglucose positron emission tomography/computed tomography accuracy in the staging of non-small cell lung cancer: review and cost-effectiveness.

Gómez León N, Escalona S, Bandrés B, Belda C, Callejo D, Blasco JA - Radiol Res Pract (2014)

Images for a 60-year-old man. (a) CT image of an NSCLC primary tumor (epidermoid carcinoma) in the right upper lobe. (b) PET image showing intense 18F-FDG uptake. (c) PET/CT image showing tumor localisation and radiotracer uptake. (d) Coronal whole-body PET image.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4238277&req=5

fig2: Images for a 60-year-old man. (a) CT image of an NSCLC primary tumor (epidermoid carcinoma) in the right upper lobe. (b) PET image showing intense 18F-FDG uptake. (c) PET/CT image showing tumor localisation and radiotracer uptake. (d) Coronal whole-body PET image.
Mentions: Forty of the 103 patients (38.8%, 36 men and four women) were classified by PET/CT and histology as candidates for surgery; nine of these patients had stage IA disease, 11 had stage IB disease, six had stage IIB disease,12 had stage IIIA disease, and two had stage IIIB disease (Figure 2).

Bottom Line: Results.Incremental cost-effectiveness of PET/CT over CT alone was €17,412 quality-adjusted life-year (QALY).Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Research Institute La Princesa, La Princesa University Hospital, C/Diego de León 62, 28006 Madrid, Spain.

ABSTRACT
Aim of the performed clinical study was to compare the accuracy and cost-effectiveness of PET/CT in the staging of non-small cell lung cancer (NSCLC). Material and Methods. Cross-sectional and prospective study including 103 patients with histologically confirmed NSCLC. All patients were examined using PET/CT with intravenous contrast medium. Those with disease stage ≤IIB underwent surgery (n = 40). Disease stage was confirmed based on histology results, which were compared with those of PET/CT and positron emission tomography (PET) and computed tomography (CT) separately. 63 patients classified with ≥IIIA disease stage by PET/CT did not undergo surgery. The cost-effectiveness of PET/CT for disease classification was examined using a decision tree analysis. Results. Compared with histology, the accuracy of PET/CT for disease staging has a positive predictive value of 80%, a negative predictive value of 95%, a sensitivity of 94%, and a specificity of 82%. For PET alone, these values are 53%, 66%, 60%, and 50%, whereas for CT alone they are 68%, 86%, 76%, and 72%, respectively. Incremental cost-effectiveness of PET/CT over CT alone was €17,412 quality-adjusted life-year (QALY). Conclusion. In our clinical study, PET/CT using intravenous contrast medium was an accurate and cost-effective method for staging of patients with NSCLC.

No MeSH data available.


Related in: MedlinePlus